

Ajanta House, Charkop, Kandivli (West), Mumbai - 400 067 India T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



28th July 2023

Scrip Code: BSE – AJANTPHARM 532331		Scrip Code: NSE AJANTPHARM EQ		
	Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051		
	BSE LIMITED	National Stock Exchange of India,		

Intimation regarding issuance of Letter of Confirmation under Regulation 39(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Pursuant to Regulation 39(3) of the SEBI LODR Regulations and in terms of SEBI Circular No. SEBI/HO/MIRSD/ MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022, the Company has approved issuance of "Letter of Confirmation" on 28th July 2023 in lieu of share certificate(s), which were reported lost by the following shareholder:

Name of Shareholder	Folio No	Old Certificate No.	New Certificate No.	Distinctive Nos.	Shares
KIRAN CHOUDHRY	000322	257	19548	217876- 224250	6375

Kindly take the above information on record.

Thanking you,

Yours faithfully,

Gaurang Shah

VP – Legal & Company Secretary

